share_log

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co.以買入評級啓動對Moleculin Biotech的報道,宣佈目標股價爲3美元
Benzinga ·  2023/12/14 19:06

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Moleculin Biotech (NASDAQ:MBRX) with a Buy rating and announces Price Target of $3.

HC Wainwright & Co. 分析師弗農·貝納迪諾以買入評級開始報道Moleculin Biotech(納斯達克股票代碼:MBRX),並宣佈目標股價爲3美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論